Revista Brasileira de Ginecologia e Obstetrícia
Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review
DOI: s-0042-1756148 - volume 44 - 2022
Ayane Cristine Alves Sarmento, Ana Paula Ferreira Costa, Juliana Lírio, José Eleutério, Pedro Vieira Baptista, Ana Katherine Gonçalves
Abstract
Objective
To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women.Data Sources We conducted a search on the PubMed, Embase, Scopus, Web of Science, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases, as well as on clinical trial databases. We analyzed studies published between 1996 and May 30, 2020. No language restrictions were applied.Selection of Studies We selected randomized clinical trials that evaluated the treatment of sexual dysfunction in postmenopausal women.Data Collection Three authors (ACAS, APFC, and JL) reviewed each article based on its title and abstract. Relevant data were subsequently taken from the full-text article. Any discrepancies during the review were resolved by consensus between all the listed authors.Data Synthesis A total of 55 studies were included in the systematic review. The approaches tested to treat sexual dysfunction were as follows: lubricants and moisturizers (18 studies); phytoestrogens (14 studies); dehydroepiandrosterone (DHEA; 8 studies); ospemifene (5 studies); vaginal testosterone (4 studies); pelvic floor muscle exercises (2 studies); oxytocin (2 studies); vaginal CO laser (2 studies); lidocaine (1 study); and vitamin E vaginal suppository (1 study).
Conclusion
We identified literature that lacks coherence in terms of the proposed treatments and selected outcome measures. Despite the great diversity in treatment modalities and outcome measures, the present systematic review can shed light on potential targets for the treatment, which is deemed necessary for sexual dysfunction, assuming that most randomized trials were evaluated with a low risk of bias according to the Cochrane Collaboration risk of bias tool. The present review is registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100488).
Full Text
Objective
To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women.
Data Sources
We conducted a search on the PubMed, Embase, Scopus, Web of Science, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases, as well as on clinical trial databases. We analyzed studies published between 1996 and May 30, 2020. No language restrictions were applied.
Selection of Studies
We selected randomized clinical trials that evaluated the treatment of sexual dysfunction in postmenopausal women.
Data Collection
Three authors (ACAS, APFC, and JL) reviewed each article based on its title and abstract. Relevant data were subsequently taken from the full-text article. Any discrepancies during the review were resolved by consensus between all the listed authors.
Data Synthesis
A total of 55 studies were included in the systematic review. The approaches tested to treat sexual dysfunction were as follows: lubricants and moisturizers (18 studies); phytoestrogens (14 studies); dehydroepiandrosterone (DHEA; 8 studies); ospemifene (5 studies); vaginal testosterone (4 studies); pelvic floor muscle exercises (2 studies); oxytocin (2 studies); vaginal CO2 laser (2 studies); lidocaine (1 study); and vitamin E vaginal suppository (1 study).
Conclusion
We identified literature that lacks coherence in terms of the proposed treatments and selected outcome measures. Despite the great diversity in treatment modalities and outcome measures, the present systematic review can shed light on potential targets for the treatment, which is deemed necessary for sexual dysfunction, assuming that most randomized trials were evaluated with a low risk of bias according to the Cochrane Collaboration risk of bias tool. The present review is registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100488).
References
1 . The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 Pt 1):355-369
2 Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD. Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95:s1-s66
3 Rosen RC, Maserejian NN, Connor MK, Krychman ML, Brown CS, Goldstein I. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Menopause. 2012;19(04):396-405
4 da Silva Lara LA, Useche B, Rosa E, Silva JC, Ferriani RA, Reis RM, Sá MF. Sexuality during the climacteric period. Maturitas. 2009;62(02):127-133
5 Davis SR. Understanding female sexual function. Menopause. 2009;16(03):425-426
6 Weinberger JM, Houman J, Caron AT, Anger J. Female sexual dysfunction: a systematic review of outcomes across various treatment modalities. Sex Med Rev. 2019;7(02):223-250
7 Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2018;229:45-56
8 . . Diagnostic and statistical manual of mental disorders: text revision (DSM-IV-TR). 2000;:-
9 Binik YM, Brotto LA, Graham CA, Segraves RT. Response of the DSM-V Sexual Dysfunctions subworkgroup to commentaries published in JSM. J Sex Med. 2010;7(07):2382-2387
10 Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Womens VIews of Treatment Options for Menopausal Vaginal Changes) survey. J Sex Med. 2013;10(07):1790-1799
11 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(07):-
12 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. . Cochrane handbook for systematic reviews of interventions. 2019;:-
13 Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol. 2011;64(04):407-415
14 Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(03):259-263
15 Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15(03):969-973
16 Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med. 2010;7(03):1284-1290
17 Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol. 2011;117(04):922-927
18 Loprinzi CL, Balcueva EP, Liu H, Sloan JA, Kottschade LA, Stella PJ. A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA. J Support Oncol. 2011;9(03):105-112
19 Fernandes T, Costa-Paiva LH, Pinto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med. 2014;11(05):1262-1270
20 Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat. 2016;158(01):79-90
21 Juliato PT, Rodrigues AT, Stahlschmidt R, Juliato CR, Mazzola PG. Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?. Climacteric. 2017;20(01):62-66
22 Seyyedi F, Kopaei MR, Miraj S. Comparison between vaginal royal jelly and vaginal estrogen effects on quality of life and vaginal atrophy in postmenopausal women: a clinical trial study. Electron Physician. 2016;8(11):3184-3192
23 Nappi RE, Cagnacci A, Becorpi AM, Nappi C, Paoletti AM, Busacca M. Monurelle Biogel vaginal gel in the treatment of vaginal dryness in postmenopausal women. Climacteric. 2017;20(05):467-475
24 Diem SJ, Guthrie KA, Mitchell CM, Reed SD, Larson JC, Ensrud KE. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial. Menopause. 2018;25(10):1086-1093
25 Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178(05):681-690
26 Mitchell CM, Guthrie KA, Larson J, Diem S, LaCroix AZ, Caan B. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women. Menopause. 2019;26(08):816-822
27 Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011;14(02):282-288
28 Le Donne M, Caruso C, Mancuso A, Costa G, Iemmo R, Pizzimenti G. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet. 2011;283(06):1319-1323
29 Grimaldi EF, Restaino S, Inglese S, Foltran L, Sorz A, Di Lorenzo G. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort. Minerva Ginecol. 2012;64(04):321-329
30 Zheng TP, Sun AJ, Xue W, Wang YP, Jiang Y, Zhang Y. Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women. Chin Med J (Engl). 2013;126(11):2034-2038
31 Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(01):69-78
32 Balk JL, Whiteside DA, Naus G, DeFerrari E, Roberts JM. A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. J Soc Gynecol Investig. 2002;9(04):238-242
33 Oh KJ, Chae MJ, Lee HS, Hong HD, Park K. Effects of Korean red ginseng on sexual arousal in menopausal women: placebo-controlled, double-blind crossover clinical study. J Sex Med. 2010;7(4 Pt 1):1469-1477
34 Amato P, Young RL, Steinberg FM, Murray MJ, Lewis RD, Cramer MA. Effect of soy isoflavone supplementation on menopausal quality of life. Menopause. 2013;20(04):443-447
35 Tedeschi C, Benvenuti C. Comparison of vaginal gel isoflavones versus no topical treatment in vaginal dystrophy: results of a preliminary prospective study. Gynecol Endocrinol. 2012;28(08):652-654
36 Lima SM, Yamada SS, Reis BF, Postigo S, Galvão da Silva MA, Aoki T. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas. 2013;74(03):252-258
37 Lima SM, Bernardo BF, Yamada SS, Reis BF, da Silva GM, Galvão MA. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial. Maturitas. 2014;78(03):205-211
38 Postigo S, Lima SM, Yamada SS, dos Reis BF, da Silva GM, Aoki T. Assessment of the effects of Tribulus terrestris on sexual function of menopausal women. Rev Bras Ginecol Obstet. 2016;38(03):140-146
39 de Souza KZ, Vale FB, Geber S. Efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women: a randomized, double-blinded, placebo-controlled trial. Menopause. 2016;23(11):1252-1256
40 Yaralizadeh M, Abedi P, Najar S, Namjoyan F, Saki A. Effect of Foeniculum vulgare (fennel) vaginal cream on vaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled trial. Maturitas. 2016;84:75-80
41 Malakouti J, Jabbari F, Asghari-Jafarabadi M, Javadzadeh Y, Farshbaf-Khalili A. The impact of ginkgo biloba tablet and aromatherapy inhaler combination on sexual function in females during postmenopausal period: a double-blind randomized controlled trial. Int J Womens Health Reprod Sci. 2017;5(02):129-136
42 Suwanvesh N, Manonai J, Sophonsritsuk A, Cherdshewasart W. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women. Menopause. 2017;24(02):210-215
43 Ghorbani Z, Mirghafourvand M, Charandabi SM, Javadzadeh Y. The effect of ginseng on sexual dysfunction in menopausal women: A double-blind, randomized, controlled trial. Complement Ther Med. 2019;45:57-64
44 Palma F, Fontanesi F, Facchinetti F, Cagnacci A. Acupuncture or phy(F)itoestrogens (E)strogen plus progestin on menopausal symptoms. A randomized study. Gynecol Endocrinol. 2019;35(11):995-998
45 Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(05):923-931
46 Genazzani AR, Stomati M, Valentino V, Pluchino N, Potì E, Casarosa E. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric. 2011;14(06):661-668
47 Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med. 2014;11(07):1766-1785
48 Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L. VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(09):950-963
49 Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi E. VVA Prasterone Group. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015;18(04):590-607
50 Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D. Members of the VVA Prasterone Research Group. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401-2412
51 Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L. VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(03):243-256
52 Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(03):480-486
53 Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(06):623-630
54 Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(02):226-232
55 Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014;78(02):91-98
56 Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(06):611-621
57 Tungmunsakulchai R, Chaikittisilpa S, Snabboon T, Panyakhamlerd K, Jaisamrarn U, Taechakraichana N. Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women. BMC Womens Health. 2015;15:113-113
58 Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(03):313-319
59 Nazarpour S, Simbar M, Ramezani Tehrani F, Alavi Majd H. Effects of sex education and kegel exercises on the sexual function of postmenopausal women: a randomized clinical trial. J Sex Med. 2017;14(07):959-967
60 Nazarpour S, Simbar M, Majd HA, Tehrani FR. Beneficial effects of pelvic floor muscle exercises on sexual function among postmenopausal women: a randomised clinical trial. Sex Health. 2018;15(05):396-402
61 Jonasson AF, Edwall L, Uvnäs-Moberg K. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int. 2011;17(04):120-125
62 Torky HA, Taha A, Marie H, El-Desouky E, Raslan O, Moussa AA. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21(02):174-178
63 Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FL, Santiago LH. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25(01):21-28
64 Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause. 2019;26(08):833-840
65 Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394-3400
66 Golmakani N, Parnan Emamverdikhan A, Zarifian A, Sajadi Tabassi SA, Hassanzadeh M. Vitamin E as alternative local treatment in genitourinary syndrome of menopause: a randomized controlled trial. Int Urogynecol J Pelvic Floor Dysfunct. 2019;30(05):831-837
67 Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet. 2011;283(03):539-543
68 Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(06):1575-1584
69 Vicariotto F, DE Seta F, Faoro V, Raichi M. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety. Minerva Ginecol. 2017;69(04):342-349
70 Leibaschoff G, Izasa PG, Cardona JL, Miklos JR, Moore RD. Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the treatment of menopausal vaginal/genitourinary symptoms. Surg Technol Int. 2016;29:149-159
71 Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;1:-
72 Peixoto C, Carrilho CG, Barros JA, Ribeiro TT, Silva LM, Nardi AE. The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric. 2017;20(02):129-137
73 Khera M. Testosterone therapy for female sexual dysfunction. Sex Med Rev. 2015;3(03):137-144
74 Reed BG, Bou Nemer L, Carr BR. Has testosterone passed the test in premenopausal women with low libido? A systematic review. Int J Womens Health. 2016;8:599-607